Gilead Sciences Inc. (GILD)
Gilead quarterly results beat Wall Street estimates
Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.
Gilead Sciences: Buy This Stock For Both Dividend And Growth
I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk versus peers. Strong profitability, efficient capital allocation, and robust dividend growth capacity underpin GILD's investment case for safety and income.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.23, denoting a +2.06% move from the preceding trading day.
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Gilead Sciences Stock Surged 21% in a Month
GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.
Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors
In the latest trading session, Gilead Sciences (GILD) closed at $141.95, marking a +1.72% move from the previous day.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
Gilead Sciences (GILD) reached $131.14 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Livdelzi, drive incremental growth and diversification. Q3 2025 results exceeded expectations, with revenue up 4% YoY and non-GAAP EPS up 22%, highlighting strong operational efficiency and margin expansion.
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. GILD guides for 2025 sales of $28.4–$28.7 billion and EPS of $8.05–$8.25, with HIV revenue forecast above $20B and a strong pipeline.
